ASX:NOX
Market Cap:
Price Delay ~20min
Interactive 2020
Annual Report

Media

11-May-2021

Outsourcing-Pharma: Clinical study shows drug has COVID-19 treatment potential. CEO Dr. Graham Kelly discusses the history of Veyonda, details of the NOXCOVID study and next steps with Jenni Spinner, editor.

Read More here

30-Apr-2021

Global Pharma Update reported, "Australian company Noxopharm has reported interim data from its NOXCOVID trial, which showed that its drug candidate Veyonda provided protection against hyper-inflammation (cytokine storm) in moderate Covid-19 patients"

Read More here

30-Apr-2021

Proactive Investors reported, "Noxopharm welcomes prestigious scientific journal reporting success of Veyonda® as booster of chemotherapy in late-stage cancer patients"

Read more here.

27-Apr-2021

Biospace reported, Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19.

Read More here

27-Apr-2021

Barron's reported: "Australian clinical-stage drug development company Noxopharm Limted (ASX:NOX) today announced that in a cohort of 18 patients with moderately severe cases of COVID-19"

Read more here.

22-Apr-2021

TrialSiteNews reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.

17-Apr-2021

SBS online reported, "Hope for men with advanced prostate cancer after Australian treatment trials".

Read more here.

14-Apr-2021

THE WALL STREET JOURNAL reported, "Noxopharm Files Septic Shock Treatment Patent for Veyonda(R)"

Read more here.

14-Apr-2021

American Pharmaceutical Review presented, "Noxopharm Files Septic Shock Treatment Patent for Veyonda®"

Read more here.

6-Apr-2021

proactive reported, "Noxopharm files patent for Veyonda® as treatment for septic shock."

Read more here.